register

News & Trends - Pharmaceuticals

‘This has the power to transform cancer treatment’, says Professor Long

Health Industry Hub | June 5, 2024 |

Pharma News: Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes and one person dying every 6 hours. In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers globally.

Results from the Phase 3 NADINA Clinical Trial, an international collaboration between Melanoma Institute Australia (MIA) and The Netherlands Cancer Institute (NKI), have just been released at the American Society of Clinical Oncology (ASCO) Annual Meeting.

“The trial results are transformative for not only the treatment of melanoma, but they set the stage and benchmark for other cancers,” said MIA Co-Medical Director Professor Georgina Long AO, who co-led the NADINA trial with her colleague Professor Christian Blank from The Netherlands Cancer Institute.

“By showing a significant decrease in the rate of recurrence and death due to melanoma for high-risk Stage III melanoma patients by using combination checkpoint inhibitor immunotherapy before rather than after surgery, we now have the clinical proof needed to change treatment protocols,” said Professor Christian Blank.

“This phase III trial is the first of its kind and is one of the single biggest developments, not only in melanoma, but the whole cancer field,” Professor Long added. “Our next step is to refine who gets what immunotherapy before surgery, as some patients will need combination and others will not,” she said.

The NADINA trial was the first phase 3 trial in oncology evaluating a neoadjuvant regimen consisting of only immunotherapy. It compared neoadjuvant (pre-surgery) treatment with combination immunotherapy (ipilimumab and nivolumab) to the current standard adjuvant (post-surgery) approach with single agent immunotherapy (nivolumab).

The international trial led by MIA’s Prof Georgina Long and NKI’s Prof Christian Blank was opened across the globe including in Europe, Australia and USA. Melanoma Institute Australia opened the trial across 8 Australian centres including MIA, Peter MacCallum Cancer Centre, Westmead Hospital, The Alfred, Tasman Health Care, Lake Macquarie Hospital, Fiona Stanley Hospital and Princess Alexandra Hospital.

Results showed estimated 12 month event-free survival (EFS) rates of 83.7% in the neoadjuvant arm vs 57.2% in the adjuvant arm.

“This trial has flipped the traditional surgery then drugs rationale on its head, and melanoma patients across the world will now benefit,’ said MIA surgeon Assoc Professor Alex van Akkooi who was involved in the trial.

“Importantly, having immunotherapy first up also means a patient’s pathological response to treatment can be determined when the tumour is surgically removed, which is critical not only in predicting long-term treatment success but also in identifying which patients require further therapy and those who may not,” added MIA Co-Medical Director Prof Richard Scolyer AO, a pathologist in the trial.

“Combination neoadjuvant, or pre-surgery, immunotherapy should now be considered a new standard of treatment for higher-risk Stage III melanoma, and should also now be clinically evaluated for use across the wider oncology field,” said Professor Long.

“NADINA shows the power of clinical trials to push science and medicine forward, and move us closer to our goal of reaching zero deaths from melanoma and saving lives across all cancers,” she said.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.